Published in Cancer Vaccine Week, April 18th, 2005
According to a study from England, "among the recent gene therapy protocols, vectors that can stably express transgenes, for example, HIV-1-based vectors, are particularly desirable. There have been no direct reports on insertional mutagenesis by lentiviral vectors; however, the severe pathogenic nature of their parental virus (HIV-1) is still a major safety concern surrounding these vectors and prevents the progress with their clinical application."
"We reason that by investigating the host response we shall be able to assess the safety and potential effects of the vectors on...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Vaccine Week